Evidence map›Paper›PMID 38687080›Full record

ArticleMicrobiology spectrum2024

Minimum inhibitory concentrations of azithromycin in clinical isolates of

Yoshifumi Uwamino, Wataru Aoki, Rika Inose, Yuka Kamoshita, Kei Mikita, Ho Namkoong, Tomoyasu Nishimura, Hiromichi Matsushita, Naoki Hasegawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antimicrobial agents and chemotherapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshifumi Uwamino *Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0001-9398-9599
Wataru Aoki *Clinical Laboratory, Keio University Hospital, Tokyo, Japan.
Rika InoseClinical Laboratory, Keio University Hospital, Tokyo, Japan.
Yuka KamoshitaDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Kei MikitaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Tomoyasu NishimuraKeio University Health Center, Tokyo, Japan.
Hiromichi MatsushitaDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0003-0717-7450

Funding

Kyokuto Pharmaceuticals, Inc. N/AMEXT | Japan Science and Technology Agency (JST) PRESTO JPMJPR22R2Oyama Health Foundation N/A
6 · The paper itself

Abstract

The latest guidelines include azithromycin as a preferred regimen for treating

Indexed as

Anti-Bacterial AgentsAzithromycinClarithromycinMicrobial Sensitivity TestsMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedAnti-Bacterial AgentsAzithromycinClarithromycinazithromycinclarithromycinminimum inhibitory concentrationMycobacterium avium complex

Identifiers

PMID38687080
PMCPMC11237530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.